Monday, January 29, 2018

TherapeuticsMD (TXMD): Hidden Opportunity In FDA Compounding ...

StreetInsider.com-4 hours ago
That outbreak, along with other FDA concerns about compounded drugs, emphasized the need for better control of compounding practices and oversight of compounding pharmacies. W e see TX-001HR, as potentially the first and only bio-identical FDA-approved combination of 17 β-estradiol and progesterone, as uniquely ...
Post a Comment